仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Eculizumab （Anti-Complement C5） is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex （MAC）. Eculizumab has the potential for haemolysis research.